Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC rearrangement + BCL2 rearrangement
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
lisocabtagene maraleucel
Sensitive: A2 - Guideline
lisocabtagene maraleucel
Sensitive
:
A2
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
lenalidomide
Sensitive: B - Late Trials
lenalidomide
Sensitive
:
B
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
rituximab
Resistant: C3 – Early Trials
rituximab
Resistant
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
lisocabtagene maraleucel
Sensitive: C3 – Early Trials
lisocabtagene maraleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
ibrutinib
Sensitive: C3 – Early Trials
ibrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
EPOCH-R
Sensitive: C3 – Early Trials
EPOCH-R
Sensitive
:
C3
EPOCH-R
Sensitive: C3 – Early Trials
EPOCH-R
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
MYC rearrangement + BCL2 rearrangement
Follicular Lymphoma
R-DHAP
Sensitive: C3 – Early Trials
R-DHAP
Sensitive
:
C3
R-DHAP
Sensitive: C3 – Early Trials
R-DHAP
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
loncastuximab tesirine-lpyl
Sensitive: C3 – Early Trials
loncastuximab tesirine-lpyl
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
C-RICE
Sensitive: C3 – Early Trials
C-RICE
Sensitive
:
C3
C-RICE
Sensitive: C3 – Early Trials
C-RICE
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
AR160
Sensitive: C3 – Early Trials
AR160
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
IACS-010759
Sensitive: D – Preclinical
IACS-010759
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
ibrutinib
Resistant: D – Preclinical
ibrutinib
Resistant
:
D
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
MYC rearrangement + BCL2 rearrangement
Non-Hodgkin’s Lymphoma
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
ibrutinib + alemtuzumab
Sensitive: D – Preclinical
ibrutinib + alemtuzumab
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
HZX-02-059
Sensitive: D – Preclinical
HZX-02-059
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
copanlisib
Sensitive: D – Preclinical
copanlisib
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
venetoclax + DUP 785
Sensitive: D – Preclinical
venetoclax + DUP 785
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
BTM-3566
Sensitive: D – Preclinical
BTM-3566
Sensitive
:
D
MYC rearrangement + BCL2 rearrangement
Lymphoma
MYC rearrangement + BCL2 rearrangement
Lymphoma
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
SGN-CD19B
Sensitive: D – Preclinical
SGN-CD19B
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login